Neurocrine reports positive results in latest Endometriosis Drug Trials

Neurocrine studied 252 patients, with a confirmed diagnosis of endometriosis. The company split the group into 3 sets for treatment over 6 months.

  • elagolix 150mg once daily  (new drug)
  • elagolix 75mg twice daily  (new drug)
  • depo provera 104 (DMPA)  (common treatment)
Elagolix showed an improvement of endometriosis symptoms following treatment.
An Improvement in endometriosis symptoms was documented against different pain scales commonly used to rate symptons of sufferers.
In addition the impact on bone density loss was statistically less than on other treatments.
Also on the news the companies shares of course edged higher.